Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 8/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11145599 | 0.98 | CSNK2A1 (0.61) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| Bromide SCHEMBL22834317 | 0.98 | CSNK2A1 (0.61) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| Pyrimidine SCHEMBL23088813 | 0.89 | CSNK2A1 (0.53) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12601168 | 0.84 | MAP4K4 (0.53) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12091997 | 0.83 | CSNK2A1 (0.62) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL15641472 | 0.82 | CYP2A6 (0.59) | CSNK2A1ALDH1A1SMN1; SMN2KDRLIMK1 | |
| SCHEMBL30279938 | 0.82 | CYP2A6 (0.59) | CSNK2A1ALDH1A1SMN1; SMN2KDRLIMK1 | |
| SCHEMBL9954813 | 0.81 | ALDH1A1 (0.54) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL29389381 | 0.81 | CSNK2A1 (0.49) | CSNK2A1NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL2406426 | 0.81 | CSNK2A1 (0.49) | CSNK2A1NPC1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028940-A | PI4K inhibitor and application thereof | 清华大学 | 2026-05-12 | — | — | CN | claimed |
| CN-118007244-A | Texturing additive for preparing monocrystalline silicon with special-shaped rough surface structure and application method thereof | 常州时创能源股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117986200-A | Preparation method of phenyl-dithiazole derivative | 烟台新药创制山东省实验室 | 2024-05-07 | — | — | CN | claimed |
| EP-4139302-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3908577-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-11-17 | — | — | EP | claimed |
| WO-2021216949-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | claimed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | claimed |
| CN-104449602-B | A kind of anti-high concentrated acid corrosion and wear-resistant inhibition lubricant and preparation method thereof | 长江大学 | 2017-10-17 | — | — | CN | claimed |
| CN-104449602-A | Corrosion inhibition lubricating agent for resisting high-concentration acid liquid corrosion and abrasion and preparation method of corrosion inhibition lubricating agent | UNIV YANGTZE | 2015-03-25 | — | — | CN | claimed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | claimed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| EP-1034176-A1 | THIOPHENE-SULFONAMIDE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-09-13 | — | — | EP | claimed |
| WO-1999028316-A1 | THIOPHENE-SULFONAMIDE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-06-10 | — | — | WO | claimed |
| CN-1006386-B | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | SHINETSU CHEM IND CO (JP) | 1990-01-10 | — | — | CN | claimed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | claimed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | claimed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | claimed |
| US-4418070-A | 5-PHENYL-THIAZOLES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1983-11-29 | — | — | US | claimed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122028940-A | PI4K inhibitor and application thereof | 清华大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4722321-A1 | GREASE COMPOSITION | KYODO YUSHI CO., LTD. (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | UNIV LELAND STANFORD JUNIOR (US) | 2025-10-23 | — | — | US | disclosed |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-06-26 | — | — | US | disclosed |
| EP-4574214-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4308573-B1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHROEDINGER INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-115466229-B | Para-amidobenzenesulfonyl compound and application thereof | 上海中医药大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-3419980-B1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | UNIV LELAND STANFORD JUNIOR (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024248035-A1 | GREASE COMPOSITION | 協同油脂株式会社 | 2024-12-05 | — | — | WO | disclosed |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240368084-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2024-11-07 | — | — | US | disclosed |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118451078-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118319866-A | Formulations comprising RET kinase inhibitors | 罗索肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4392410-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS FOR USE AS THERAPEUTICS | The University of British Columbia (CA) | 2024-07-03 | — | — | EP | disclosed |
| CN-118234498-A | STING modulators, compositions, and methods of use thereof | 南佛罗里达大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199634-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-118007244-A | Texturing additive for preparing monocrystalline silicon with special-shaped rough surface structure and application method thereof | 常州时创能源股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-117986200-A | Preparation method of phenyl-dithiazole derivative | 烟台新药创制山东省实验室 | 2024-05-07 | — | — | CN | disclosed |
| US-11963950-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11884657-B2 | PI-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024020534-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4308573-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2024006956-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-111148743-B | Inhibition of ubiquitin-specific peptidase 30 | 福马治疗有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117120447-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3054936-B1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-116490507-A | Heterocyclic condensation CDC7 kinase inhibitors for the treatment of cancer | 薛定谔公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4211140-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Schrödinger, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| CN-111630052-B | Dihydroindazinone derivatives | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-111971286-B | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230090520-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2023-03-23 | — | — | US | disclosed |
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-03-14 | — | — | US | disclosed |
| WO-2023034587-A1 | STING Modulators, Compositions, and Methods of Use | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023023853-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS FOR USE AS THERAPEUTICS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-03-02 | — | — | WO | disclosed |
| EP-4139302-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| CN-115515948-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11530211-B2 | Dihydroindolizinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-20 | — | — | US | disclosed |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-115466229-A | P-acylamino benzenesulfonyl compound and application thereof | 上海中医药大学 | 2022-12-13 | — | — | CN | disclosed |
| EP-4081526-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2022-10-27 | — | — | US | disclosed |
| CN-111278822-B | Crystalline forms | 阿雷生物药品公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-4069369-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022197898-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220288069-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-3390391-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220267270-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA | 2022-08-25 | — | — | US | disclosed |
| WO-2022164789-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS | SCHRÖDINGER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-3523302-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-4021449-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | University of South Florida (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3999064-A1 | INHIBITORS OF TYROSINE KINASE | Bridgene Biosciences, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220153711-A1 | P14-Kinase Inhibitors and Methods of Using the Same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| US-20220153711-A1 | P14-Kinase Inhibitors and Methods of Using the Same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| EP-3998107-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | Tokyo Institute of Technology (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114401722-A | Inhibitors of tyrosine kinases | 布里奇恩生物科学公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3974426-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-109790169-B | Cyanopyrrolidine derivatives having activity as USP30 inhibitors | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022055963-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-11274077-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114174275-A | PI 4-kinase inhibitors and methods of use thereof | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| CN-114174275-A | PI 4-kinase inhibitors and methods of use thereof | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3941909-A1 | PI4-KINASE INHIBITORS AND METHODS OF USING THE SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941909-A1 | PI4-KINASE INHIBITORS AND METHODS OF USING THE SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220017507-A1 | PI-Kinase Inhibitors with Anti-Infective Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-20 | — | — | US | disclosed |
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3908577-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3908577-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| WO-2021216949-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| WO-2021188938-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-17 | — | — | US | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| CN-108368089-B | Deubiquitinase inhibitor | 特殊治疗有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. | 2021-03-25 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20210053965-A1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3394049-B1 | CYANOPYRROLIDINE DERVIVATIVES AS INHBITORS FOR DUBS | MISSION THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| WO-2021016102-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021016102-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2020264176-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20200392077-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-17 | — | — | US | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| EP-3741757-A1 | DIHYDROINDOLIZINONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2020-11-25 | — | — | EP | disclosed |
| CN-106413402-B | Hepatitis b core protein allosteric modulators | 美国印第安纳大学研究和技术公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| CN-108290872-B | Cyanopyrrolidine derivatives as DUBs inhibitors | 特殊治疗有限公司 | 2020-10-02 | — | — | CN | disclosed |
| WO-2020191205-A1 | PI4-KINASE INHIBITORS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191205-A1 | PI4-KINASE INHIBITORS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | WO | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-10752581-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3692028-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | Forma Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-25 | — | — | US | disclosed |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-25 | — | — | US | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| CN-111148743-A | Inhibition of ubiquitin-specific peptidase 30 | 福马治疗有限公司 | 2020-05-12 | — | — | CN | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| CN-107001339-B | Novel compounds | 特殊治疗有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-10590075-B2 | Cyanopyrrolidine derivatives as inhibitors for DUBs | MISSION THERAPEUTICS LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| CN-110437153-A | hepatitis B core protein allosteric modulators | UNIV INDIANA RES & TECH CORP | 2019-11-12 | — | — | CN | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-10-29 | — | — | US | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| EP-3556755-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| US-10428060-B2 | PI-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190276395-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-09-12 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| EP-3523294-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Blade Therapeutics, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3519412-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| WO-2019142883-A1 | DIHYDROINDOLIZINONE DERIVATIVE | 第一三共株式会社 | 2019-07-25 | — | — | WO | disclosed |
| CN-110023304-A | Calpain regulator and its therapeutical uses | 布莱德治疗公司 | 2019-07-16 | — | — | CN | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| CN-109790169-A | With the Cyanopyrolidine derivatives as USP30 inhibitor activity | 特殊治疗有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-10266488-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| EP-3442952-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | Genfit (FR) | 2019-02-20 | — | — | EP | disclosed |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3419980-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | The Board of Trustees of the Leland Stanford Junior University (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| EP-3416960-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| US-20180362460-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| EP-3394049-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | Mission Therapeutics Limited (GB) | 2018-10-31 | — | — | EP | disclosed |
| EP-3390391-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| CN-108699035-A | Noval chemical compound | 特殊治疗有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20180273521-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporationt (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2018-09-20 | — | — | US | disclosed |
| EP-2763532-B1 | PI-KINASE INHIBITORS WITH BROAD SPECTRUM ANTI-INFECTIVE ACTIVITY | UNIV LELAND STANFORD JUNIOR (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10077411-B2 | Grease composition | KYODO YUSHI CO., LTD. (JP) | 2018-09-18 | — | — | US | disclosed |
| CN-108368089-A | Novel Compounds | 特殊治疗有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9987259-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| WO-2018060742-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018060742-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926309-B2 | Pi-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| CN-105228982-B | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | 拜耳制药股份公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017178174-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-19 | — | — | WO | disclosed |
| CN-104449602-B | A kind of anti-high concentrated acid corrosion and wear-resistant inhibition lubricant and preparation method thereof | 长江大学 | 2017-10-17 | — | — | CN | disclosed |
| US-20170290814-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-12 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| WO-2017147526-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| CN-107001339-A | Novel compounds | 特殊治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2017109488-A1 | CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2017-06-22 | — | — | US | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2017-06-22 | — | — | US | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9617281-B2 | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE S.A. (ES) | 2017-04-11 | — | — | US | disclosed |
| US-9617281-B2 | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE S.A. (ES) | 2017-04-11 | — | — | US | disclosed |
| US-9617281-B2 | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE S.A. (ES) | 2017-04-11 | — | — | US | disclosed |
| CN-104520304-B | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | 埃斯特韦实验室有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106413402-A | Hepatitis b core protein allosteric modulators | 美国印第安纳大学研究和技术公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
| EP-3116316-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research And Technology Corporation (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20170001955-A1 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase | THOMAS JEFFERSON UNIVERSITY | 2017-01-05 | — | — | US | disclosed |
| EP-2668185-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-11-23 | — | — | EP | disclosed |
| US-9499567-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-11-22 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2870164-B1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2016-09-14 | — | — | EP | disclosed |
| EP-2870164-B1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2016-09-14 | — | — | EP | disclosed |
| US-20160237079-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMA (US) | 2016-08-18 | — | — | US | disclosed |
| EP-3054936-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | Eastern Virginia Medical School (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-20160228414-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-08-11 | — | — | US | disclosed |
| US-9409903-B2 | Benzyl substituted triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409903-B2 | Benzyl substituted triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-20160177213-A1 | GREASE COMPOSITION | KYODO YUSHI CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3029132-A1 | GREASE COMPOSITION | Kyodo Yushi Co., Ltd. (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-103154018-B | For passing through the antibody of affinity chromatography and the part of Fc-fusion protein purification | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-04-27 | — | — | CN | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| CN-105492582-A | Grease composition | KYODO YUSHI | 2016-04-13 | — | — | CN | disclosed |
| US-9309236-B2 | PI-kinase inhibitors with broad spectrum anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
| US-9271976-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | disclosed |
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-18 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249131-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105228982-A | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| CN-102791718-B | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20150322088-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| EP-2152271-B1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015138895-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015138895-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-17 | — | — | WO | disclosed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9120821-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-01 | — | — | US | disclosed |
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-102725287-B | 1,3, 4-oxadiazole-2-carboxamide compounds | PHARMA IP GENERAL INC ASS | 2015-07-01 | — | — | CN | disclosed |
| US-20150166574-A1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2015-06-18 | — | — | US | disclosed |
| US-20150166574-A1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2015-06-18 | — | — | US | disclosed |
| US-20150166574-A1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2015-06-18 | — | — | US | disclosed |
| CN-102573480-B | Triazine derivatives and their therapeutic use | CALIFORNIA CAPITAL EQUITY LLC | 2015-06-10 | — | — | CN | disclosed |
| EP-2870164-A1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-05-13 | — | — | EP | disclosed |
| CN-103339131-B | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO LTD | 2015-05-13 | — | — | CN | disclosed |
| US-20150111901-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOBPHARMACEUTICALS CO LTD (KR) | 2015-04-23 | — | — | US | disclosed |
| WO-2015054662-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2015-04-16 | — | — | WO | disclosed |
| CN-104520304-A | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | ESTEVE LABOR DR | 2015-04-15 | — | — | CN | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| CN-104449602-A | Corrosion inhibition lubricating agent for resisting high-concentration acid liquid corrosion and abrasion and preparation method of corrosion inhibition lubricating agent | UNIV YANGTZE | 2015-03-25 | — | — | CN | disclosed |
| WO-2015025172-A1 | 5-ARYL-THIAZOL-2-YL-AMINE COMPOUNDS AND THEIR THERAPEUTIC USE | CHARLES MARK DAVID (GB) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057285-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057285-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150051193-A1 | PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-02-19 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-8952165-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-02-10 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-20150025076-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-22 | — | — | US | disclosed |
| US-20140350012-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-27 | — | — | US | disclosed |
| WO-2014145642-A9 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| US-8877924-B2 | Benzyl substituted triazine derivatives and their therapeutical applications | NantBio Inc. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877924-B2 | Benzyl substituted triazine derivatives and their therapeutical applications | NantBio Inc. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853415-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014145642-A2 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8835437-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-16 | — | — | US | disclosed |
| US-8815909-B2 | Diaminocyclohexane compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815909-B2 | Diaminocyclohexane compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815909-B2 | Diaminocyclohexane compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2763532-A1 | PI-KINASE INHIBITORS WITH BROAD SPECTRUM ANTI-INFECTIVE ACTIVITY | The Board of Trustees of The Leland Stanford Junior University (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| CN-102066384-B | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2014-07-30 | — | — | CN | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741939-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2719696-A1 | NOVEL KINASE INHIBITORS | Asinex Limited (RU) | 2014-04-16 | — | — | EP | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072995-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014006130-A1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014006130-A1 | IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-01-09 | — | — | WO | disclosed |
| EP-2682395-A1 | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-01-08 | — | — | EP | disclosed |
| EP-2682395-A1 | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-01-08 | — | — | EP | disclosed |
| EP-2668185-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130296340-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-11-07 | — | — | US | disclosed |
| CN-103339131-A | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO LTD | 2013-10-02 | — | — | CN | disclosed |
| US-20130252333-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-26 | — | — | US | disclosed |
| US-20130252333-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-26 | — | — | US | disclosed |
| US-20130252333-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-26 | — | — | US | disclosed |
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| CN-103154018-A | Ligands for antibody and Fc-fusion protein purification by affinity chromatography | GRAFFINITY PHARMACEUTICALS GMBH | 2013-06-12 | — | — | CN | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431605-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2013052845-A1 | PI-KINASE INHIBITORS WITH BROAD SPECTRUM ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2013012827-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012827-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2012169934-A1 | NOVEL KINASE INHIBITORS | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "АСИНЭКС МЕДХИМ" (RU) | 2012-12-13 | — | — | WO | disclosed |
| CN-101678014-B | Heterocyclic kinase modulators | SGX PHARMACEUTICALS INC | 2012-12-12 | — | — | CN | disclosed |
| CN-102791718-A | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2012-11-21 | — | — | CN | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120264759-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264759-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-18 | — | — | US | disclosed |
| CN-102725287-A | 1,3, 4-oxadiazole-2-carboxamide compounds | PHARMA IP GENERAL INC ASS | 2012-10-10 | — | — | CN | disclosed |
| WO-2012129562-A2 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-2493892-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2012102583-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-08-02 | — | — | WO | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| CN-101296914-B | Derivatives with PPAR agonist activity | SHIONOGI & CO | 2012-07-18 | — | — | CN | disclosed |
| CN-102573480-A | Triazine derivatives and their therapeutic use | ABRAXIS BIOSCIENCE LLC | 2012-07-11 | — | — | CN | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-2440057-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-7998990-B2 | 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| CN-101448801-B | 5-Phenyl-thiazol-2-yl-urea derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG | 2011-06-15 | — | — | CN | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| CN-102066384-A | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2011-05-18 | — | — | CN | disclosed |
| WO-2011053292-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-05 | — | — | WO | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2297097-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| CN-1838953-B | Phosphatidylinositol 3-kinase (PI) for the treatment of inflammatory airway diseases3) Inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives | NOVARTIS AG | 2011-02-02 | — | — | CN | disclosed |
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| EP-2271650-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2010144394-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144550-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144550-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-7691896-B2 | Analogs of salinosporamide A | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-06 | — | — | US | disclosed |
| CN-101678014-A | heterocyclic kinase modulators | SGX PHARMACEUTICALS INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2162132-A1 | HETEROCYCLIC KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2152271-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2010-02-17 | — | — | EP | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009152356-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2009-12-17 | — | — | WO | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| CN-100532370-C | Acylaminothiazole derivatives, process for their preparation and their use as inhibitors of beta-amyloid peptide production | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | CN | disclosed |
| EP-1931679-A4 | ANALOGS OF SALINOSPORAMIDE A | HARVARD COLLEGE (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7563903-B2 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-07-21 | — | — | US | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| CN-101448801-A | 5-Phenyl-thiazol-2-yl-urea derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029562-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054665-A1 | ANALOGS OF SALINOSPORAMIDE A | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008148840-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008144767-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| CN-101296914-A | Derivatives with PPAR agonist activity | SHIONOGI & CO (JP) | 2008-10-29 | — | — | CN | disclosed |
| EP-1590337-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME AS BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS | SANOFI AVENTIS (FR) | 2008-08-13 | — | — | EP | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1931679-A1 | ANALOGS OF SALINOSPORAMIDE A | The President and Fellows of Harvard College (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-03-06 | — | — | US | disclosed |
| WO-2007134827-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-7288659-B2 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2007-10-30 | — | — | US | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007021897-A1 | ANALOGS OF SALINOSPORAMIDE A | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| EP-1514112-B1 | METHOD FOR IDENTIFYING AN ALLOSTERIC EFFECTOR OF A RECEPTOR | CENTRE NAT RECH SCIENT (FR) | 2006-09-06 | — | — | EP | disclosed |
| US-20060194259-A1 | Method for isolating an allosteric effector of a receptor | UNIVERSITE LOUIS PASTEUR DE STRASSOURG (FR) | 2006-08-31 | — | — | US | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| EP-1664006-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| CN-1777593-A | Acylaminothiazole derivatives, process for their preparation and their use as inhibitors of beta-amyloid peptide production | SANOFI AVENTIS (FR) | 2006-05-24 | — | — | CN | disclosed |
| US-7037929-B1 | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2006-05-02 | — | — | US | disclosed |
| US-20060052426-A1 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | US | disclosed |
| EP-1417189-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-12-14 | — | — | EP | disclosed |
| EP-1590337-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME AS BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS | Sanofi-Aventis (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-20050176789-A1 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-11 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2005026137-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1514112-A2 | METHOD FOR ISOLATING AN ALLOSTERIC EFFECTOR OF A RECEPTOR | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI (FR) | 2004-09-02 | — | — | US | disclosed |
| WO-2004067520-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME AS BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | WO | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| EP-1417189-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003107004-A2 | METHOD FOR ISOLATING AN ALLOSTERIC EFFECTOR OF A RECEPTOR | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2003-12-24 | — | — | WO | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| EP-1343561-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003014095-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-02-20 | — | — | WO | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| CN-1325389-A | 2-aminothiazole derivatives, process for preparing the same and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | disclosed |
| CN-1325390-A | 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | disclosed |
| EP-0872903-B1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | SHINETSU CHEMICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6277519-B1 | QUENCHING AN ALLOY MELT; COMMINUTION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1034176-A1 | THIOPHENE-SULFONAMIDE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-09-13 | — | — | EP | disclosed |
| US-6096144-A | TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| WO-1999028316-A1 | THIOPHENE-SULFONAMIDE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-06-10 | — | — | WO | disclosed |
| US-5858571-A | TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0872903-A1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | Shin-Etsu Chemical Co., Ltd. (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5646098-A | Carbonyl containing compounds and their derivatives as multi-functional fuel and lube additives | EXXON CHEMICAL PATENTS INC (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0589985-A1 | 2-AMINO-4-ARYL-THIAZOLES WITH ANTIASTHMATIC AND ANTI-INFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1994-04-06 | — | — | EP | disclosed |
| EP-0398425-B1 | Antirhinoviral piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA NV (BE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0554332-A4 | INHIBITION OF POLYMERIZATION ON INTERIOR SURFACES USING PAINT CONTAINING PHENOTHIAZINE | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0554332-A1 | INHIBITION OF POLYMERIZATION ON INTERIOR SURFACES USING PAINT CONTAINING PHENOTHIAZINE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1993000342-A1 | 2-AMINO-4-ARYL-THIAZOLES WITH ANTIASTHMATIC AND ANTI-INFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-01-07 | — | — | WO | disclosed |
| EP-0519449-A1 | 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-12-23 | — | — | EP | disclosed |
| WO-1992006799-A1 | INHIBITION OF POLYMERIZATION ON INTERIOR SURFACES USING PAINT CONTAINING PHENOTHIAZINE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-30 | — | — | WO | disclosed |
| US-5068130-A | Inhibition of polymer formation on surfaces including vents by using an inhibitor paint | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| US-5057505-A | Treatment of illnesses attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0274346-B1 | SUBSTITUTED AMINOMETHANE-DIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1991-03-06 | — | — | EP | disclosed |
| EP-0398425-A1 | Antirhinoviral piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| CN-1006386-B | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | SHINETSU CHEM IND CO (JP) | 1990-01-10 | — | — | CN | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| EP-0274346-A1 | Substituted aminomethane-diphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-13 | — | — | EP | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
| US-4418070-A | 5-PHENYL-THIAZOLES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1983-11-29 | — | — | US | disclosed |
| US-4233214-A | FOR POLYACRYLONITRILE AND ACID-MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-11 | — | — | US | disclosed |
| US-4161571-A | GELATION INHIBITORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-07-17 | — | — | US | disclosed |
| US-4104268-A | POLYACRYLONITRILE, POLYESTERS, POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-01 | — | — | US | disclosed |
| US-4080493-A | POLYBUTADIENE, POLYISOPRENE, GELATION INHIBITOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-03-21 | — | — | US | disclosed |
| US-4036826-A | Cationic azo dyestuffs with a hydroxyalkylated ammonium group | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111901-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | CSNK2A1 781/4885NPC1 1612/4885ALDH1A1 2259/4885 |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CSNK2A1 610/4885NPC1 896/4885ALDH1A1 1082/4885 |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | ACAT1, GLS2, GLS | CSNK2A1 824/4885NPC1 217/4885ALDH1A1 163/4885 |
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | NFE2L2, KEAP1, GSTK1 | CSNK2A1 1321/4885NPC1 755/4885ALDH1A1 1059/4885 |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | CSNK2A1 624/4885NPC1 3540/4885ALDH1A1 1180/4885 |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CSNK2A1 610/4885NPC1 896/4885ALDH1A1 1082/4885 |
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | CSNK2A1 790/4885NPC1 184/4885ALDH1A1 264/4885 |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | CSNK2A1 58/4885NPC1 1759/4885ALDH1A1 3059/4885 |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CSNK2A1 126/4885NPC1 2197/4885ALDH1A1 4193/4885 |
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | CSNK2A1 1812/4885NPC1 3113/4885ALDH1A1 2580/4885 |
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | CSNK2A1 3493/4885NPC1 6/4885ALDH1A1 399/4885 |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | CSNK2A1 1431/4885NPC1 1991/4885ALDH1A1 799/4885 |
| US-10266488-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | ALOX12, ALOX15, ALOX15B | CSNK2A1 4588/4885NPC1 4611/4885ALDH1A1 3051/4885 |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | CSNK2A1 2033/4885NPC1 3091/4885ALDH1A1 2267/4885 |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | CSNK2A1 1486/4885NPC1 1090/4885ALDH1A1 646/4885 |
| US-20200392077-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE | ALOX12, ALOX15, ALOX15B | CSNK2A1 4588/4885NPC1 4611/4885ALDH1A1 3051/4885 |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, DLAT | CSNK2A1 1729/4885NPC1 91/4885ALDH1A1 488/4885 |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CSNK2A1 599/4885NPC1 1425/4885ALDH1A1 1695/4885 |
| US-11274077-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | ALOX12, ALOX15, ALOX15B | CSNK2A1 4588/4885NPC1 4611/4885ALDH1A1 3051/4885 |
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | CSNK2A1 3428/4885NPC1 138/4885ALDH1A1 3109/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CSNK2A1 610/4885NPC1 896/4885ALDH1A1 1082/4885 |
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | NPY4R, NPY2R, NPY1R | CSNK2A1 1134/4885NPC1 2907/4885ALDH1A1 3102/4885 |
| US-20210380562-A1 | Novel Compounds | USP30, USP20, USP10 | CSNK2A1 968/4885NPC1 2862/4885ALDH1A1 1020/4885 |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | CSNK2A1 735/4885NPC1 4274/4885ALDH1A1 3241/4885 |
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK4, GRK4, NR4A1 | CSNK2A1 98/4885NPC1 2987/4885ALDH1A1 3640/4885 |
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | PI4KB, PI4KA, PI4K2A | CSNK2A1 1471/4885NPC1 3837/4885ALDH1A1 4695/4885 |
| US-20150057285-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, BAZ2B, PRKCZ | CSNK2A1 66/4885NPC1 2701/4885ALDH1A1 4143/4885 |
| US-20220267270-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | STING1, IRF3, CGAS | CSNK2A1 789/4885NPC1 2240/4885ALDH1A1 4798/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CSNK2A1 126/4885NPC1 2197/4885ALDH1A1 4193/4885 |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CSNK2A1 489/4885NPC1 2700/4885ALDH1A1 2216/4885 |
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | CSNK2A1 522/4885NPC1 3064/4885ALDH1A1 3226/4885 |
| US-20150051193-A1 | PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity | PIP4K2A, PIP5K1A, PIP4K2C | CSNK2A1 1060/4885NPC1 4136/4885ALDH1A1 4834/4885 |
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | CSNK2A1 440/4885NPC1 2436/4885ALDH1A1 300/4885 |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | CSNK2A1 391/4885NPC1 652/4885ALDH1A1 4634/4885 |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | CSNK2A1 943/4885NPC1 953/4885ALDH1A1 4382/4885 |
| US-20080058380-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PARK7, ACAT1, APP | CSNK2A1 1157/4885NPC1 1624/4885ALDH1A1 508/4885 |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, DGAT2 | CSNK2A1 1794/4885NPC1 98/4885ALDH1A1 590/4885 |
| US-11130748-B2 | Compounds | USP30, USP20, USP10 | CSNK2A1 978/4885NPC1 2796/4885ALDH1A1 1021/4885 |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | USP30, UCHL1, UCHL3 | CSNK2A1 1643/4885NPC1 2635/4885ALDH1A1 448/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CSNK2A1 40/4885NPC1 1945/4885ALDH1A1 4421/4885 |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | CSNK2A1 1431/4885NPC1 1991/4885ALDH1A1 799/4885 |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | CSNK2A1 522/4885NPC1 3064/4885ALDH1A1 3226/4885 |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | PLK1, DCK, CSNK1A1 | CSNK2A1 14/4885NPC1 1011/4885ALDH1A1 2801/4885 |
| US-10640498-B2 | Compounds | USP30, USP20, UBQLN1 | CSNK2A1 1038/4885NPC1 1767/4885ALDH1A1 648/4885 |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | CNKSR1, CDK8, MAPK8 | CSNK2A1 80/4885NPC1 1587/4885ALDH1A1 4033/4885 |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CSNK2A1 610/4885NPC1 896/4885ALDH1A1 1082/4885 |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | CSNK2A1 224/4885NPC1 3892/4885ALDH1A1 2527/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | CSNK2A1 242/4885NPC1 3745/4885ALDH1A1 2453/4885 |
| US-11963950-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | CSNK2A1 522/4885NPC1 3064/4885ALDH1A1 3226/4885 |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP1, USP28 | CSNK2A1 512/4885NPC1 3506/4885ALDH1A1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.